{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T03:54:15Z","timestamp":1771559655846,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Wallenberg Foundation"},{"name":"S\u00f6derbergs foundation"},{"name":"IMTAC"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.clim.2013.05.021","type":"journal-article","created":{"date-parts":[[2013,6,13]],"date-time":"2013-06-13T06:31:43Z","timestamp":1371105103000},"page":"73-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Treatment of inflammatory bowel disease by chemokine receptor-targeted leukapheresis"],"prefix":"10.1016","volume":"149","author":[{"given":"Michael","family":"Eberhardson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Marits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Karlen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mats","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"Cotton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry","family":"Woznica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Maltman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Glise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ola","family":"Winqvist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2013.05.021_bb0005","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nrgastro.2009.232","article-title":"The pharmacoeconomics of biologic therapy for IBD","volume":"7","author":"Cohen","year":"2010","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.clim.2013.05.021_bb0010","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1146\/annurev-immunol-030409-101225","article-title":"Inflammatory bowel disease","volume":"28","author":"Kaser","year":"2010","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.clim.2013.05.021_bb0015","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.crohns.2010.04.004","article-title":"Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects","volume":"4","author":"Allez","year":"2010","journal-title":"J. Crohn's Colitis"},{"key":"10.1016\/j.clim.2013.05.021_bb0020","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ajg.2010.392","article-title":"The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?","volume":"106","author":"D'Haens","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.clim.2013.05.021_bb0025","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ajg.2011.103","article-title":"Assessing response and loss of response to biological therapies in IBD","volume":"106","author":"Yanai","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.clim.2013.05.021_bb0030","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of Infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2013.05.021_bb0035","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1111\/j.1440-1746.2010.06407.x","article-title":"Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience","volume":"25","author":"Lawrance","year":"2010","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.clim.2013.05.021_bb0040","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/MEG.0b013e3283479125","article-title":"Safety of Infliximab in 10years of clinical practice","volume":"23","author":"O'Donnell","year":"2011","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.clim.2013.05.021_bb0045","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nri1132","article-title":"The immunological and genetic basis of inflammatory bowel disease","volume":"3","author":"Bouma","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.clim.2013.05.021_bb0050","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2249.1991.tb02958.x","article-title":"Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease","volume":"86","author":"McCarthy","year":"1991","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clim.2013.05.021_bb0055","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1136\/jcp.33.10.917","article-title":"Monocytes in inflammatory bowel disease: absolute monocyte counts","volume":"33","author":"Mee","year":"1980","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.clim.2013.05.021_bb0060","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jtbi.2010.03.027","article-title":"Model of colonic inflammation: immune modulatory mechanisms in inflammatory bowel disease","volume":"264","author":"Wendelsdorf","year":"2010","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.clim.2013.05.021_bb0065","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1146\/annurev.immunol.24.021605.090529","article-title":"Chemokine: receptor structure, interactions, and antagonism","volume":"25","author":"Allen","year":"2007","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.clim.2013.05.021_bb0070","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1600-065X.2006.00482.x","article-title":"Generation of gut-homing T cells and their localization to the small intestinal mucosa","volume":"215","author":"Johansson-Lindbom","year":"2007","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.clim.2013.05.021_bb0075","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2249.2010.04279.x","article-title":"The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review","volume":"163","author":"Hanai","year":"2011","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clim.2013.05.021_bb0080","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.2174\/138161209788489104","article-title":"Recent understanding of leukocytapheresis (LCAP) for the treatment of inflammatory bowel disease","volume":"15","author":"Mitsuyama","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.clim.2013.05.021_bb0085","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1471-230X-10-73","article-title":"Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease","volume":"10","author":"Lindberg","year":"2010","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.clim.2013.05.021_bb0090","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.transci.2010.07.023","article-title":"Leukocytapheresis in the treatment of inflammatory bowel disease: current position and perspectives","volume":"43","author":"Vernia","year":"2010","journal-title":"Transfus. Aspher. Sci."},{"key":"10.1016\/j.clim.2013.05.021_bb0095","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/j.gastro.2008.04.023","article-title":"A randomized, double-blind, sham-controlled study of granulocyte\/monocyte apheresis for active ulcerative colitis","volume":"135","author":"Sands","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clim.2013.05.021_bb0100","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1038\/ctg.2012.23","article-title":"HLA-DR(hi) and CCR9 define a pro-inflammatory monocyte subset in IBD","volume":"3","author":"Linton","year":"2012","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.clim.2013.05.021_bb0105","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.gastro.2006.12.038","article-title":"A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis","volume":"132","author":"D'Haens","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clim.2013.05.021_bb0110","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1053\/gast.2001.27154","article-title":"CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease","volume":"121","author":"Papadakis","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clim.2013.05.021_bb0115","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.4049\/jimmunol.178.5.3293","article-title":"Phenotype and effector function of CC chemokine receptor 9-expressing lymphocytes in small intestinal Crohn's disease","volume":"178","author":"Saruta","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2013.05.021_bb0120","doi-asserted-by":"crossref","first-page":"7598","DOI":"10.4049\/jimmunol.178.12.7598","article-title":"Impaired accumulation of antigen-specific CD8 lymphocytes in chemokine CCL25-deficient intestinal epithelium and lamina propria","volume":"178","author":"Wurbel","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2013.05.021_bb0125","doi-asserted-by":"crossref","first-page":"6347","DOI":"10.1073\/pnas.0609180104","article-title":"CCR9 is a homing receptor for plasmacytoid dendritic cells to the small intestine","volume":"104","author":"Wendland","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2013.05.021_bb0130","doi-asserted-by":"crossref","first-page":"e16442","DOI":"10.1371\/journal.pone.0016442","article-title":"CCL25\/CCR9 interactions regulate large intestinal inflammation in a murine model of acute colitis","volume":"6","author":"Wurbel","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2013.05.021_bb0135","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1053\/j.gastro.2006.08.031","article-title":"Antibody blockade of CCL25\/CCR9 ameliorates early but not late chronic murine ileitis","volume":"131","author":"Rivera-Nieves","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clim.2013.05.021_bb0140","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1124\/jpet.110.169714","article-title":"Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease","volume":"335","author":"Walters","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.clim.2013.05.021_bb0145","doi-asserted-by":"crossref","first-page":"e60094","DOI":"10.1371\/journal.pone.0060094","article-title":"Prospective randomized oral-therapy evaluation in Crohn's disease trial-1 Study, a randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease","volume":"8","author":"Keshav","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2013.05.021_bb0150","article-title":"One-year results from PROTECT-1 study of intestine-specific chemokine receptor antagonist CCX282-B (Traficet-EN) in Crohn's disease","author":"Hetzel","year":"2010"},{"key":"10.1016\/j.clim.2013.05.021_bb0155","article-title":"CCR9 inhibition in the treatment of colonic inflammation","author":"Jaen","year":"2010"},{"key":"10.1016\/j.clim.2013.05.021_bb0160","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1042\/BST0340422","article-title":"The biological relevance of chemokine\u2013proteoglycan interactions","volume":"34","author":"Proudfoot","year":"2006","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.clim.2013.05.021_bb0165","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/clpt.2011.328","article-title":"Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms","volume":"91","author":"Ordas","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.clim.2013.05.021_bb0170","first-page":"24","article-title":"Biocompatibility: complement as mediator of tissue damage and as indicator of incompatibility","volume":"14","author":"Mollnes","year":"1997","journal-title":"Exp. Clin. Immunogenet."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152166161300171X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152166161300171X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T05:51:31Z","timestamp":1539582691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152166161300171X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S152166161300171X"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2013.05.021","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of inflammatory bowel disease by chemokine receptor-targeted leukapheresis","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2013.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The Authors. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}